The pathological progression of cardiovascular and Cerebrovascular Diseases is closely related to the abnormal activation of RAAS, but its specific mechanism and dynamic regulatory network remain unclear. This study aims to reveal the occurrence and development of cardiovascular and cerebrovascular diseases and the related mechanism of RAAS's involvement in neuroinflammation and vascular remodeling affecting prognosis through regulating blood pressure, which is expected to provide a new target for the treatment of cardiovascular and cerebrovascular diseases.
GazianoTA. Cardiovascular diseases worldwide. Public Health Approach Cardiovasc Dis Prev Manag2022; 1: 8–18.
2.
ZhouMWangHZengX, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet2019; 394: 1145–1158.
3.
Roldán-MonteroRPérez-SáezJMCerro-PardoI, et al.Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm. Sci Adv2022; 8: eabm7322.
4.
RothGAMensahGAJohnsonCO, et al.Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol2020; 76: 2982–3021.
5.
Suárez-RiveroJMPastor-MaldonadoCJPovea-CabelloS, et al.From mitochondria to atherosclerosis: the inflammation path. Biomedicines2021; 9: 8–106.
6.
RupareliaNChoudhuryR. Inflammation and atherosclerosis: what is on the horizon?Heart2020; 106: 80–85.
7.
SongXChenWZhaoX, et al.Decreased flow in ischemic stroke with coexisting intracranial artery stenosis and white matter hyperintensities. J Cent Nerv Syst Dis2024; 16: 11795735241266572.
8.
TognolaCMalobertiAVarrentiM, et al.Myocardial infarction with nonobstructive coronary arteries (MINOCA): current insights into pathophysiology, diagnosis, and management. Diagnostics (Basel)2025; 15. DOI:10.3390/diagnostics15070942
9.
DaliMBogleCMEBogleRG. The evolving paradigm of myocardial infarction in the era of artificial intelligence. Br J Hosp Med (Lond)2025; 86: –7.
10.
IbanezBJamesSAgewallS, et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J2018; 39: 119–177.
11.
TileaIVargaASerbanRC. Past, present, and future of blood biomarkers for the diagnosis of acute myocardial infarction—promises and challenges. Diagnostics2021; 11: 881.
12.
VagoJPAmaralFAvan de LooFAJ. Resolving inflammation by TAM receptor activation. Pharmacol Ther2021; 227: 107893.
13.
ZhuangBZhongCMaY, et al.Innovative therapeutic strategies for myocardial infarction across various stages: non-coding RNA and stem cells. Int J Mol Sci2024; 26: 231.
14.
FatimaSYadavN. Nutraceutical and nanonutraceutical in the management of CVD and hypertension. In Handbook of nutraceuticals: science, technology and engineering. Springer, 2023, pp.1–38.
15.
StanawayJDAfshinAGakidouE, et al.Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet2018; 392: 1923–1994.
16.
FanYHouCPengL, et al.Twenty-Four-Hour ambulatory blood pressure variability associated with cerebral small vessel disease MRI burden and its progression in inpatients with cerebrovascular disease. Front Neurol2020; 11: 513067.
17.
WeiWMaDLiL, et al.Cognitive impairment in cerebral small vessel disease induced by hypertension. Neural Regen Res2024; 19: 1454–1462.
18.
Ramírez-MeloLMEstrada-LunaDRubio-RuizME, et al.Relevance of lipoprotein composition in endothelial dysfunction and the development of hypertension. Int J Mol Sci2025; 26. DOI:10.3390/ijms26031125
19.
KhalafKChamiehMWelcN, et al.Cellular aspects of immunity involved in the development of atherosclerosis. Front Immunol2025; 16: 1461535.
20.
MayerlCLukasserMSedivyR, et al.Atherosclerosis research from past to present–on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch2006; 449: 96–103.
MinelliSMinelliPMontinariMR. Reflections on atherosclerosis: lesson from the past and future research directions. J Multidiscip Healthc2020; 13: 621–633.
23.
HanssonGKLibbyP. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol2006; 6: 508–519.
24.
ZhaoLZhaiZHouW. Analysis of Carotid color ultrasonography and high sensitive C-reactive protein in patients with atherosclerotic cerebral infarction. Pak J Med Sci2016; 32: 931–934.
25.
RattanakrongNSiriphornABoonyongS. Incidence and risk factors associated with falls among women with breast cancer during taxane-based chemotherapy. Support Care Cancer2022; 30: 7499–7508.
26.
MaidaCDNorritoRLDaidoneM, et al.Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches. Int J Mol Sci2020; 21. DOI:10.3390/ijms21186454
27.
AlsughayyirJAlmalkiYAlburaykI, et al.Prevalence of transfusion-transmitted infections in Saudi Arabia blood donors: a nationwide, cross-sectional study. Saudi Med J2022; 43: 1363–1372.
28.
SuJHLuoMYLiangN, et al.Interleukin-6: a novel target for cardio-cerebrovascular diseases. Front Pharmacol2021; 12: 745061.
29.
LiuXQuanN. Microglia and CNS interleukin-1: beyond immunological concepts. Front Neurol2018; 9: 8.
30.
MadhurMSElijovichFAlexanderMR, et al.Hypertension: do inflammation and immunity hold the key to solving this epidemic?Circ Res2021; 128: 908–933.
31.
SchroderKZhouRTschoppJ. The NLRP3 inflammasome: a sensor for metabolic danger?Science2010; 327: 296–300.
32.
BauernfeindFGHorvathGStutzA, et al.Cutting edge: nF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol2009; 183: 787–791.
33.
HaneklausMO'NeillLACollRC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol2013; 25: 40–45.
34.
BasnetNChoHSapkotaA, et al.Blocking S1P(4) signaling attenuates brain injury in mice with ischemic stroke. J Adv Res2025. DOI:10.1016/j.jare.2025.02.012
35.
Martínez-VieyraIHernández-RojoIRosales-GarcíaVH, et al.Oxidative stress and cytoskeletal reorganization in hypertensive erythrocytes. Antioxidants (Basel)2024; 14. DOI:10.3390/antiox14010005
36.
Di ChiaraTDel CuoreADaidoneM, et al.Pathogenetic mechanisms of hypertension–brain-induced complications: focus on molecular mediators. Int J Mol Sci2022; 23: 2445.
37.
MontezanoACTouyzRM. Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research. Antioxid Redox Signal2014; 20: 164–182.
38.
YamaguchiHGuagliardoNABellLA, et al.Inhibition of renin release, a crucial event in homeostasis, is mediated by coordinated calcium oscillations within juxtaglomerular cell clusters. bioRxiv2025. DOI:10.1101/2024.12.23.629519
39.
NádasyGLBallaADörnyeiG, et al.Direct vascular effects of Angiotensin II (a systematic short review). Int J Mol Sci2024; 26. DOI:10.3390/ijms26010113
40.
SparksMACrowleySDGurleySB, et al.Classical Renin-Angiotensin system in kidney physiology. Compr Physiol2014; 4: 1201–1228.
41.
GomezRASequeira-LopezMLS. Renin cells in homeostasis, regeneration and immune defence mechanisms. Nat Rev Nephrol2018; 14: 231–245.
42.
YamaguchiHGomezRASequeira-LopezMLS. Renin cells, from vascular development to blood pressure sensing. Hypertension2023; 80: 1580–1589.
43.
WatanabeHBelyeaBCPaxtonRL, et al.Renin cell baroreceptor, a nuclear mechanotransducer central for homeostasis. Circ Res2021; 129: 262–276.
44.
HaoXLongXFanL, et al.Prenatal LPS leads to increases in RAS expression within the PVN and overactivation of sympathetic outflow in offspring rats. Hypertens Res2024; 47: 2363–2376.
45.
CaoWLiALiJ, et al.Reno-Cerebral reflex activates the renin-angiotensin system, promoting oxidative stress and renal damage after ischemia reperfusion injury. Antioxid Redox Signal2017; 27: 415–432.
46.
OsbornJWTyshynskyRVulchanovaL. Function of renal nerves in kidney physiology and pathophysiology. Annu Rev Physiol2021; 83: 429–450.
47.
YamaguchiMAlmeidaLFYamaguchiH, et al.Transformation of the kidney into a pathological neuro-immune-endocrine organ. Circ Res2024; 135: 1025–1027.
48.
NakamuraAJohnsEJ. Effect of renal nerves on expression of renin and angiotensinogen genes in rat kidneys. Am J Physiol1994; 266: E230–E241.
49.
WangJLiuMZhangX, et al.Physiological and pathophysiological implications of PGE(2) and the PGE(2) synthases in the kidney. Prostaglandins Other Lipid Mediat2018; 134: –6.
50.
GauthierMMHayozSBanekCT. Neuroimmune interplay in kidney health and disease: role of renal nerves. Auton Neurosci2023; 250: 103133.
51.
de BoerRASchrotenNFBakkerSJ, et al.Plasma renin and outcome in the community: data from PREVEND. Eur Heart J2012; 33: 2351–2359.
52.
ChengYLiuXZhangL, et al.Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells. Mol Med Rep2015; 11: 4341–4344.
53.
UnkartJTAllisonMAAbdelmalekJA, et al.Relation of plasma renin activity to subclinical peripheral and coronary artery disease (from the multiethnic study of atherosclerosis). Am J Cardiol2020; 125: 1794–1800.
54.
AcharyaKRGregoryKSSturrockED. Advances in the structural basis for angiotensin-1 converting enzyme (ACE) inhibitors. Biosci Rep2024; 44. DOI:10.1042/bsr20240130
55.
HusainKHernandezWAnsariRA, et al.Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem2015; 6: 209.
56.
BrasierARRecinosAEledrisiMS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol2002; 22: 1257–1266.
57.
LaurentSAgabiti-RoseiCBrunoRM, et al.Microcirculation and macrocirculation in hypertension: a dangerous cross-link?Hypertension2022; 79: 479–490.
58.
EhlersMRRiordanJF. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry1989; 28: 5311–5318.
59.
NakamuraYYamazakiYTezukaY, et al.Expression of CYP11B2 in aldosterone-producing adrenocortical adenoma: regulatory mechanisms and clinical significance. Tohoku J Exp Med2016; 240: 183–190.
60.
EkmanNGrossmanABNieckarzA, et al.Non-Hypertensive effects of aldosterone. Int J Mol Sci2025; 26. DOI:10.3390/ijms26020540
61.
SoundararajanRPearceDZieraT. The role of the ENaC-regulatory complex in aldosterone-mediated sodium transport. Mol Cell Endocrinol2012; 350: 242–247.
62.
FunderJWCareyRMManteroF, et al.The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab2016; 101: 1889–1916.
63.
JambartIKassabRGannagé-YaredMH, et al.High prevalence of primary aldosteronism in a tertiary care hospital in Lebanon. Medicine (Baltimore)2025; 104: e41384.
64.
Ruiz-SanchezJGFernandez SanchezÁCardenas-SalasJ, et al.Primary aldosteronism prevalence enhanced by strict adherence to 2016 Endocrine Society guidelines: insights from an endocrine hypertension unit. J Hypertens2024; 42: 1813–1822.
65.
MemonSSLilaABarnabasR, et al.Prevalence of primary aldosteronism in type 2 diabetes mellitus and hypertension: a prospective study from Western India. Clin Endocrinol (Oxf)2022; 96: 539–548.
66.
MatsumotoTOkiKKajikawaM, et al.Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism. Hypertension2015; 65: 841–848.
67.
Sutton-TyrrellKNajjarSSBoudreauRM, et al.Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation2005; 111: 3384–3390.
68.
McCurleyAPiresPWBenderSB, et al.Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med2012; 18: 1429–1433.
69.
CooperJNTepperPBarinas-MitchellE, et al.Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults. Clin Exp Hypertens2012; 34: 63–70.
LiuZXieBPangS, et al.Aldosterone's impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection. Am J Transl Res2024; 16: 4246–4255.
72.
NguyenGDelarueFBurckléC, et al.Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest2002; 109: 1417–1427.
73.
QuadriSSCooperCGhaffarD, et al.The pathological role of pro(renin) receptor in renal inflammation. J Exp Pharmacol2021; 13: 339–344.
HoffmannNPetersJ. Functions of the (pro)renin receptor (Atp6ap2) at molecular and system levels: pathological implications in hypertension, renal and brain development, inflammation, and fibrosis. Pharmacol Res2021; 173: 105922.
76.
XieSSongSLiuS, et al.(Pro)renin receptor mediates tubular epithelial cell pyroptosis in diabetic kidney disease via DPP4-JNK pathway. J Transl Med2024; 22: 26.
77.
FangHDengMZhangL, et al.Role of (pro)renin receptor in albumin overload-induced nephropathy in rats. Am J Physiol Renal Physiol2018; 315: F1759–f1768.
78.
HsiehYCLeeKCLeiHJ, et al.(Pro)renin receptor knockdown attenuates liver fibrosis through inactivation of ERK/TGF-β1/SMAD3 pathway. Cell Mol Gastroenterol Hepatol2021; 12: 813–838.
79.
YoshidaAKanamoriHNaruseG, et al.(Pro)renin receptor blockade ameliorates heart failure caused by chronic kidney disease. J Card Fail2019; 25: 286–300.
80.
SeravalleGGrassiG. Sympathetic nervous system, hypertension, obesity and metabolic syndrome. High Blood Press Cardiovasc Prev2016; 23: 175–179.
81.
GamboaAFigueroaRParanjapeSY, et al.Autonomic blockade reverses endothelial dysfunction in obesity-associated hypertension. Hypertension2016; 68: 1004–1010.
82.
GatineauEGongMCYiannikourisF. Soluble prorenin receptor increases blood pressure in high fat-fed male mice. Hypertension2019; 74: 1014–1020.
83.
WimalawansaSJ. Unveiling the interplay-Vitamin D and ACE-2 molecular interactions in mitigating complications and deaths from SARS-CoV-2. Biology (Basel)2024; 13. DOI:10.3390/biology13100831
84.
WolfGWenzelUBurnsKD, et al.Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int2002; 61: 1986–1995.
85.
Espitia-CorredorJABozaPEspinoza-PérezC, et al.Angiotensin II triggers NLRP3 inflammasome activation by a Ca(2+) signaling-dependent pathway in rat cardiac fibroblast Ang-II by a Ca(2+)-dependent mechanism triggers NLRP3 inflammasome in CF. Inflammation2022; 45: 2498–2512.
86.
GonzálezGERhalebNED'AmbrosioMA, et al.Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J Hypertens2015; 33: 144–152.
87.
SatouRMiyataKGonzalez-VillalobosRA, et al.Interferon-γ biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. Faseb J2012; 26: 1821–1830.
88.
HarrisonDGPatrickDM. Immune mechanisms in hypertension. Hypertension2024; 81: 1659–1674.
89.
WeeCLAzemiAKMokhtarSS, et al.Vitamin D deficiency enhances vascular oxidative stress, inflammation, and Angiotensin II levels in the microcirculation of diabetic patients. Microvasc Res2023; 150: 104574.
90.
ZhengEWarchołIMejzaM, et al.Exploring anti-inflammatory treatment as upstream therapy in the management of atrial fibrillation. J Clin Med2025; 14: 82.
91.
ArendshorstWJVendrovAEKumarN, et al.Oxidative stress in kidney injury and hypertension. Antioxidants (Basel)2024; 13. DOI:10.3390/antiox13121454
92.
WenzelPKnorrMKossmannS, et al.Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation2011; 124: 1370–1381.
93.
De CiuceisCAmiriFBrassardP, et al.Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol2005; 25: 2106–2113.
94.
KoEAAmiriFPandeyNR, et al.Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. Am J Physiol Heart Circ Physiol2007; 292: H1789–H1795.
95.
LanTHHuangXQTanHM. Vascular fibrosis in atherosclerosis. Cardiovasc Pathol2013; 22: 401–407.
96.
DibbsZIDiwanANemotoS, et al.Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation2003; 108: 1002–1008.
97.
Guitart-MampelMUrquizaPBorgesJI, et al.Impact of aldosterone on the failing myocardium: insights from mitochondria and adrenergic receptors signaling and function. Cells2021; 10. DOI:10.3390/cells10061552
98.
FunderJWPearcePTSmithR, et al.Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology1989; 125: 2224–2226.
99.
BrownNJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol2013; 9: 459–469.
100.
PacurariMKafouryRTchounwouPB, et al.The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam2014; 2014: 689360. DOI:10.1155/2014/689360
101.
BrillaCGPickRTanLB, et al.Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res1990; 67: 1355–1364.
102.
BuffoloFTettiMMulateroP, et al.Aldosterone as a mediator of cardiovascular damage. Hypertension2022; 79: 1899–1911.
103.
TeradaYUedaSHamadaK, et al.Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1. Clin Exp Nephrol2012; 16: 81–88.
104.
FerreiraNSTostesRCParadisP, et al.Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens2021; 34: 15–27.
105.
BundaSWangYMittsTF, et al.Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. J Biol Chem2009; 284: 16633–16647.
106.
GuHChenZDuN, et al.The effects of aldosterone on hypertension-associated kidney injury in a Tg-hAS mouse model. Biology (Basel)2024; 13. DOI:10.3390/biology13121084
107.
DzauVJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension2001; 37: 1047–1052.
108.
GuoHWeiDLiuR, et al.A novel therapeutic strategy for atherosclerosis: autophagy-dependent cholesterol efflux. J Physiol Biochem2022; 78: 557–572.
109.
WeissDSorescuDTaylorWR. Angiotensin II and atherosclerosis. Am J Cardiol2001; 87: 25c–32c.
110.
DuewellPKonoHRaynerKJ, et al.NLRP3 Inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature2010; 464: 1357–1361.
111.
BrownNJ. Aldosterone and vascular inflammation. Hypertension2008; 51: 161–167.
112.
CaprioMNewfellBGla SalaA, et al.Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res2008; 102: 1359–1367.
113.
DikalovSINazarewiczRR. Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxid Redox Signaling2013; 19: 1085–1094.
114.
ZhihaoLJingyuNLanL, et al.SERCA2a: A key protein in the Ca 2+ cycle of the heart failure. Heart Fail Rev2020; 25: 523–535.
115.
KalogerisTBainesCPKrenzM, et al.Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol2012; 298: 229–317.
SomannaNKYariswamyMGaraglianoJM, et al.Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2. Cell Signal2015; 27: 1928–1938.
118.
DostalDEBoozGWBakerKM. Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Mol Cell Biochem1996; 157: 15–21.
119.
RosenkranzS. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res2004; 63: 423–432.
120.
WeberKT. Aldosterone in congestive heart failure. N Engl J Med2001; 345: 1689–1697.
121.
DíezJ. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich)2007; 9: 546–550.
122.
WeidauerSLanfermannHRaabeA, et al.Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke2007; 38: 1831–1836.
123.
ZhangMMaoYRamirezS, et al.Angiotensin II induced cerebral microvascular inflammation and increased blood–brain barrier permeability via oxidative stress. Neuroscience2010; 171: 852–858.
124.
WangM-DWangYXiaY-P, et al.High serum MiR-130a levels are associated with severe perihematomal edema and predict adverse outcome in acute ICH. Mol Neurobiol2016; 53: 1310–1321.
125.
BernsJS. Review: angiotensin-converting enzyme inhibitors reduce the progression of nondiabetic renal disease. ACP J Club2002; 136: 12.
126.
NattelSBursteinBDobrevD. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol2008; 1: 62–73.
127.
TsaiCTChiangFTTsengCD, et al.Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol2010; 55: 758–770.
128.
IwasakiYKNishidaKKatoT,et al.Atrial fibrillation pathophysiology: implications for management. Circulation2011; 124: 2264–2274.
129.
HouAShiDHuangH, et al.Inflammation pathways as therapeutic targets in angiotensin II induced atrial fibrillation. Front Pharmacol2025 Mar 3; 16: 1515864.. PMID: 40098617; PMCID: PMC11911380.
130.
HealeyJSBaranchukACrystalE, et al.Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol2005; 45: 1832–1839.
131.
HuangSLiJLiQ, et al.Cardiomyopathy: pathogenesis and therapeutic interventions. MedComm2024; 5: e772.
132.
HuangLXiongSLiuH, et al.Bioinformatics analysis of the inflammation-associated lncRNA-mRNA coexpression network in type 2 diabetes. J Renin Angiotensin Aldosterone Syst2023; 2023: 6072438.
133.
ParvingHHLehnertHBröchner-MortensenJ, et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001; 345: 870–878.
134.
ShahAHHorlickEMKassM, et al.The pathophysiology of patent foramen ovale and its related complications. Am Heart J2024 Nov; 277: 76–92.. Epub 2024 Aug 10. PMID: 39134216.
135.
DevendraGPRaneAAKrasuskiRA. Provoked exercise desaturation in patent foramen ovale and impact of percutaneous closure. JACC Cardiovasc Intervent2012; 5: 416–419.
136.
SinghVTewariJQidwaiKA, et al.Safety and efficacy of novel RNA interference therapeutic agent zilebesiran in people with hypertension: a systematic review and meta-analysis. Cureus2025; 17: e77607.
137.
MorganESTamiYHuK, et al.Antisense inhibition of angiotensinogen with IONIS-AGT-L(Rx): results of phase 1 and phase 2 studies. JACC Basic Transl Sci2021; 6: 485–496.
138.
DesaiASWebbDJTaubelJ, et al.Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med2023; 389: 228–238.
139.
WangXOuyangMYangJ, et al.Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev2021; 10: Cd000024.
140.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 372: 71.
141.
ButcherKSNgKSheridanP, et al.Dabigatran treatment of acute noncardioembolic ischemic stroke. Stroke2020; 51: 1190–1198.
142.
RamadhanRNRampenganDDPulingIM, et al.Efficacy of angiotensin receptor neprilysin inhibitor in hypertension management: a systematic review and meta-analysis of clinical trials. Narra J2024; 4: e1247.
143.
ChenXHocherC-FShenL, et al.Reno-and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench. Am J Physiol-Cell Physiol2023; 325: C661–C681.
144.
DingLHLiuDXuM, et al.Enalapril inhibits tubulointerstitial inflammation and NLRP3 inflammasome expression in BSA-overload nephropathy of rats. Acta Pharmacol Sin2014; 35: 1293–1301.
145.
DuezHPourcetB. Nuclear receptors in the control of the NLRP3 inflammasome pathway. Front Endocrinol (Lausanne)2021; 12: 630536.
146.
MishraSRMahapatraKKBeheraBP, et al.Mitochondrial dysfunction as a driver of NLRP3 inflammasome activation and its modulation through mitophagy for potential therapeutics. Int J Biochem Cell Biol2021; 136: 106013.
147.
KrishnanSMLingYHHuuskesBM, et al.Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res2019; 115: 776–787.
148.
Di RaimondoDTuttolomondoAButtàC, et al.Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr Pharm Des2012; 18: 4385–4413.
149.
PatelSNFatimaNAliR, et al.Emerging role of angiotensin AT2 receptor in anti-inflammation: an update. Curr Pharm Des2020; 26: 492–500.
150.
CollRCRobertsonAAChaeJJ, et al.A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med2015; 21: 248–255.
151.
McMurrayJJPackerMDesaiAS, et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med2014; 371: 993–1004.
152.
ThompsonPLNidorfSM. Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial. J Thorac Dis2018; 10: 695–698.
153.
SzetoHHLiuSSoongY, et al.Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol2011; 22: 1041–1052.
154.
MartyniakATomasikPJ. A new perspective on the Renin-Angiotensin system. Diagnostics (Basel)2022; 13: 16.. PMID: 36611307; PMCID: PMC9818283.
155.
BaderMAleninaNAndrade-NavarroMA,et al.Mas and its related G protein-coupled receptors, Mrgprs. Pharmacol Rev2014; 66: 1080–1105.
156.
BarzegarMStokesKYChernyshevO, et al.The role of the ACE2/MasR axis in ischemic stroke: new insights for therapy. Biomedicines2021; 9: 1667.. PMID: 34829896; PMCID: PMC8615891.
157.
BennionDMHaltiganERegenhardtRW, et al.Neuroprotective mechanisms of the ACE2–Angiotensin-(1–7)–Mas axis in stroke. Curr Hypertens Rep2015; 17: 3.
158.
LiuZLiuJXiaoM, et al.Mesenchymal stem cell-derived microvesicles alleviate pulmonary arterial hypertension by regulating renin-angiotensin system. J Am Soc Hypertens2018; 12: 470–478.
159.
Pena SilvaRAHeistadDD. Promising neuroprotective effects of the angiotensin-(1–7)-angiotensin-converting enzyme 2-Mas axis in stroke. Exp Physiol2014; 99: 342–343.
160.
MeccaAPRegenhardtRWO’ConnorTE, et al.Cerebroprotection by angiotensin-(1–7) in endothelin-1-induced ischaemic stroke. Exp Physiol2011; 96: 1084–1096.
161.
TamargoMTamargoJ. Future drug discovery in Renin-Angiotensin-aldosterone system intervention. Expert Opin Drug Discov2017; 12: 827–848.
162.
HundemerGLAgharaziiMMadoreF, et al.Sex-specific associations of aldosterone and renin with body composition: a population-based cohort study. J Clin Endocrinol Metab2025; 110: 801–810.. PMID: 39148442; PMCID: PMC11834704.
163.
ReckelhoffJF. Sex and sex steroids in cardiovascular - renal physiology and pathophysiology. Gender Med2008; 5: S1–S2.
164.
SandbergKJiH. Why can't a woman be more like a man: ls the angiotensin type 2 receptor to blame or to thank. Hypertension2008; 52: 615–617.
165.
KangAKMillerJA. Effects of gender on the renin- angiotensin system, blood pressure, and renal function. Curr Hypertens Rep2002; 4: 143–151.
166.
SandbengKJiH. Sex and the renin angiotensin system; implications for gender differences in the progression of kidney disease. Adv Renal Replace Th2003; 10: 15–23.
